

Erratum corrigé

“Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice”

L. Leon, L. Rodriguez-Rodriguez, D. Freitas, L. Arietti, I. Morado, C. Vellido, J.R. Lamas, B. Fernandez, J.A. Jover, L. Abasolo

Published in: *Clin Exp Rheumatol* 2017; 35 (Suppl. 103): S165-70.

The authors have brought to our attention that there was an error in Tables I and II and have asked us to publish the tables in their correct form.

Table I. Baseline demographic and clinical characteristics of patients.

Patients (n)	108
Courses of MTX treatment	137
Total follow up patient*year	244
Women, n (%)	88 (81.5)
Mean age at diagnosis, mean \pm SD	6.6 \pm 6.5
Comorbidities, n (%)	
PAH	69 (63.9)
Hypercholesterolemia	40 (37)
Cardiovascular disease	35 (32.4)
Congestive heart failure	13 (12)
Diabetes Mellitus	20 (18.5)
Polymyalgia rheumatica	17 (15.7)
Depression	15 (13.8)
Liver disease	3 (2.7)
Peptic ulcer disease	6 (5.5)
Renal insufficiency	6 (5.5)
Symptomatic vertebral fracture	9 (8.3)
Cancer	7 (6.4)
COPD	11 (10.2)
ESR (mm/h), median [p25-p75]	85 [63-104]
Temporal Positive artery biopsy, n (%)	63 (58)
Lag time in months from diagnosis to MTX, median [p25-p75]	0.95 [0.12-2.9]
MTX dose (mg/week) at diagnosis, mean \pm SD	9.85 \pm 1
Aspirin at diagnosis, n (%)	39 (36)
Statins at diagnosis, n (%)	23 (21)
Glucocorticoids, n (%)	107 (99)
Glucocorticoids dose (mg/día) at diagnosis, mean \pm SD	50.7 \pm 16
Clinical symptoms:	
Headache	94 (87)
General symptoms	68 (62.9)
Polymyalgia rheumatica	61 (56.4)
Jaw claudication	43 (40.2)
Abnormal temporal artery	41 (37.9)
Visual disturbances	38 (35.2)
Peripheral joint pain	15 (13.8)
Glucocorticoids at 6 months, mean \pm SD	22.5 \pm 8.5

MTX: methotrexate.

Table II. Incidence rate (IR) of MTX discontinuation by gender, cause, calendar and causes.

	Patients*year	Events (n)	IR	95% CI
Total	244	91	37.26	[30.3 – 45.7]
Gender				
Women	212	70	32.9	[26.1 – 41.6]
Men	32	21	66.1	[43.1 – 101.3]
Age categories				
60-75	99	37	37.2	[27 – 51.4]
75-85	130	41	31.4	[23 – 42.7]
>85	15	13	88	[51.1 – 151.6]
Calendar time				
1990 – 1995	13	10	78	[41.9 – 144.9]
1996 – 2000	17	12	71	[40.5 – 125.6]
2001 – 2005	57	23	40.3	[26.7 – 60.5]
2006 – 2010	119	35	29.3	[21.05 – 40.8]
>2011	38	11	28.9	[16 – 52.2]
Discontinuation causes				
ADR	244	51	20.8	[15.8 – 27.4]
Moderate		37	15.1	[10.9 – 20.9]
Severe		4	1.6	[0.6-4.36]
ADR Death		14	5.7	[3.4-9.6]
ADR Infections		31	12.6	[8.9-18]
Sustained clinical response		20	8.2	[5.3 – 12.7]
Inefficacy		7	2.8	[1.3 – 6.0]
Patient decision		7	2.8	[1.3 – 6.0]
Other medical causes		7	2.8	[1.3 – 6.0]